Lab Leaders and AI Experts Back Mandatory DNA Synthesis Screening

Coalition of researchers and security officials backs mandatory DNA synthesis screening

On June 3, 2026, an open letter signed by life sciences researchers, AI technologists, national security experts, and former White House officials called on U.S. lawmakers to codify mandatory screening of synthetic nucleic acid orders and synthesis equipment. The letter was organized by the Institute for Progress and the Foundation for American Innovation.

The signatories include CEOs of major biotech labs, AI safety organizations, and luminaries in public health and national security. The ask is specific: mandate that DNA synthesis providers screen orders for concerning sequences, verify customer legitimacy before shipment, and maintain records of orders and sequence data to enable traceability for biosecurity investigations.

This is not a new concern. The International Gene Synthesis Consortium formed in 2009 to develop voluntary safeguards after protocols to reconstruct viruses from DNA were published. Many large synthesis providers already screen and record orders voluntarily. The letter frames mandatory screening as a natural codification of existing industry practice, not a new burden.

AI is eroding the knowledge barriers that have historically prevented bad actors from obtaining biological weapons

The timing driver is not new biosecurity risk. It is the pace of AI progress. The letter notes that AI systems now outperform PhD-level virologists on technical laboratory procedures within their domains of expertise. The evidence of what this means for present-day biosecurity threats is "genuinely mixed," but the trajectory is clear: knowledge barriers are eroding.

Critically, support for mandatory screening does not depend on any particular view of AI risk. The biosecurity case for screening has been recognized by scientists and governments for decades. The letter presents screening as "one of the best understood and least disruptive biosecurity measures available." It is not a speculative policy; it is formalized practice made law.

The coalition itself signals the political reality. When AI safety skeptics and AI safety organizations agree on something, it is because the measure works independent of how you think about AI. This is rare in biosecurity policy and suggests Congress has an opening to act without waiting for deeper AI-risk consensus.

Know what your synthesis vendor screens and begin preparing for federal standards

Biotech operations and compliance teams should audit their current DNA synthesis vendors against IGSC guidelines. Mandatory screening will require sequence flagging against a defined list of pathogens and sequences of concern, customer identity verification, and order recordkeeping. Vendors already doing this have no new burden. Those with gaps now have clarity on what federal law will require.

The letter explicitly calls for Congress to act "this session" and notes that states should implement standards based on federal guidelines to avoid a patchwork. This is not a distant policy proposal. If Congress moves, implementation timelines will be measured in months, not years.

For research institutions and biotech firms that depend on rapid DNA synthesis, the mandatory model is familiar territory. The measure does not prohibit synthesis; it adds identity verification and an audit trail. The real question is not whether screening works, but whether the screening protocols are standardized across providers and regulators so that compliance is clear.